Abstract:Rui Zhang, 1, &ast Jianguo Zhao, 1, &ast Lu Zhao 2 1 Department of Thyroid and Breast Surgery, Wuhan No.1 Hospital, Wuhan, 430030, People's Republic of China; 2 Department of Thyroid and Breast Surgery, Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lu Zhao, Department of Thyroid and Breast Surgery, Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, No. 1095 of Jiefang Avenue, Wuhan, 430030, People's Republic of China, Email Background: Overexpression of hypoxia-inducible factors led to tumor angiogenesis and tumor progression. However, unlike HIF-1α, the role of EPAS1/HIF-2α in papillary thyroid carcinoma (PTC) was unknown. Here, we aimed to investigate the role of EPAS1/HIF-2α in PTC. Material and Methods: EPAS1/HIF-2α expression of fresh frozen tumor samples and adjacent tissues in Tongji Hospital of 46 PTC patients was detected by RT-PCR. Gene expression datasets of PTC patients were gained from The Cancer Genome Atlas (TCGA) database. The Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene set enrichment analysis (GSEA) were used to explore the potential biological function of EPAS1/HIF-2α. The effect of EPAS1/HIF-2α on immune microenvironment of PTC was analyzed in R package "estimate". The sensitivity to various targeted drugs was quantified in R package "pRRophetic", while the sensitivity to immunotherapy was estimated based on TCIA website. Results: We found higher EPAS1/HIF-2α mRNA expression in PTC was associated with lower N stage, M stage, and better progression-free time (PFS) and disease-free time (DFS). Further, biological function analysis indicated that EPAS1/HIF-2α was mainly involved in PI3K-Akt signaling pathway. EPAS1/HIF-2α expression was positively related with CD8+ T cell infiltration and negatively related to PD-L1 expression and tumor mutation burden. Patients with low EPAS1/HIF-2α expression were more than likely to get a profit from Sorafenib, Dabrafenib, Cetuximab, Bosutinib, and immune checkpoint blockade. Conclusion: Our results suggested that EPAS1/HIF-2α played an unanticipated tumor-suppressive role in PTC. EPAS1/HIF-2α contributed to anti-tumor immunity by promoting CD8+ T cell infiltration and inhibiting PD-L1 expression in PTC. Keywords: endothelial PAS domain-containing protein 1, EPAS1, prognosis, papillary thyroid carcinoma, immunotherapy, tumor mutation burden Papillary thyroid carcinoma (PTC) has significantly increased in the world over the past few decades, 1 and it is the third most common solid malignancy. 2 Most patients with PTC anticipated a relatively satisfactory clinical prognosis under the traditional therapy. 3 However, part of PTC patients still posed the surgeons and oncologists a particularly difficult therapeutic challenge. Hence, a further exploration of the underlying molecular mechanisms involved in the unusually high aggressiveness events of PTC patients is clinically significant. 4 Hypoxia is one of the key triggers for tumor cell migration and survival, which may induce aggressive molecular potentiality of malignant tumors. 5 Moreover, HIFs are involved in the process of tumor immune escape. Under hypoxic microenvironment, activated HIFs induce activation of PD-1/PD-L1 pathway for tumor cascade events. 6 HIFα is comprised of 3 alpha-subunits - HIF-1/2/3α, 7 and it has been extensively studied in association with various human cancers. 8 Hypoxia-inducible factor 2 alpha (HIF-2α), also known as Endothelial PAS domain-containing protein 1 (EPAS1) has been demonstrated in the past researches inducing tumor progression and growth in renal cancer 9 and pancreatic cancer. 10 Islam has shown that HIF-2α plays a tumor-promotion role in the esophageal squamous cell carcinoma. 11 By contrast, HIF-2α was reported to inhibit progression of renal cell carcinoma. 12 Similarly, HIF-2α was lower expressed in sarcoma relative to normal tissue and inhibited sarcoma proliferation through mTORC1 signaling. Whereby, HIF-2α is silenced during cancer progression in many cancers. 13 Overexpression of HIF-2α increased tumor cell apoptosis and inhibited cell proliferation in glioma tumors, 14 lung tumor 15 and neuroblastoma tumor. 16 Whether HIF-2α expression in PTC participates in the activation of signaling pathways that construct an immune microenvironment remains unknown. Xu reported that HIF- -Abstract Truncated-

Current views on the role of HIF-2α in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma

EPAS1-related pheochromocytoma/paraganglioma

Pheochromocytoma–Paraganglioma Syndrome: A Multiform Disease with Different Genotype and Phenotype Features

The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma

SAT631 EPAS1 Mutations In Three Adjacent Nucleotides Resulting In Different Phenotypes

Comprehensive in silico and functional studies for classification of EPAS1/HIF2A genetic variants identified in patients with erythrocytosis

Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas

Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma

Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome

EPAS1‐mutated paragangliomas associated with haemoglobin disorders

EPAS1/HIF-2α Acts as an Unanticipated Tumor-Suppressive Role in Papillary Thyroid Carcinoma

Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas

PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma.

SDHA related phaeochromocytoma and paraganglioma: review and clinical management

Novel Gene Variants in a Nationwide Cohort of Patients with Pheochromocytoma and Paraganglioma

[Advance in HIF expression and immune microenvironment in pseudohypoxic HNPGL]

Genetic Predisposition to Pheochromocytoma and Paraganglioma: 21 Years' Experience in the Field

Pheochromocytoma/Paraganglioma Syndrome Type 1 Presenting with Atypical Symptoms and a Novel Pathogenic Variant in the SDHD Gene: A Case Report

A Hif1 Alpha Regulatory Loop Links Hypoxia And Mitochondrial Signals In Pheochromocytomas

Metastatic Pheochromocytomas and Abdominal Paragangliomas